Biotech

All Articles

A closer look at Intense Biotech's Intense 15

.In this particular full week's episode of "The Leading Pipe," our team are actually diving into Tou...

Lilly encounters phase 2 failure of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's event commemorating the commendation ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of notable management hirings, firings as w...

Lykos will definitely talk to FDA to reassess its selection adhering to denial of MDMA treatment for post-traumatic stress disorder

.Observing a bad revealing for Lykos Rehabs' MDMA prospect for post-traumatic stress disorder at a l...

AN 2 fifty percents headcount, ceases phase 3 trial after data dissatisfy

.AN2 Rehabs is reassessing its own business in action to lackluster midphase information, swearing t...

Merck pays out $700M for bispecific, spying autoimmune position and also opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 million upfront to test Amgen in a blood cancer cells ma...

Gilead pays out J&ampJ $320M to exit licensing offer for seladelpar

.Along With Gilead Sciences about to an FDA selection for its own liver disease drug seladelpar, the...

' All palms on deck' at Lilly as peers target weight problems market

.Chief executive officer David Ricks can easily see the companies setting up camping tents at baseca...

Entero laying off staff, abandoning office and pausing R&ampD

.Cushion Liquidators has transformed Entero Therapeutics white colored as a sheet. The creditor orde...

Exelixis falls ADC after choosing it's no match for Tivdak

.Exelixis is losing hope on its cells aspect (TF)- targeting antibody-drug conjugate after ending th...